Tag Archives: targeted photoimmunotherapy

Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer

March 31, 2024 by Modulight Content
No comments
Published in: Cancer Letters Authors: Hiroshi Fukushima, Seiichiro Takao, Aki Furusawa, Vladimir Valera Romero, Sandeep Gurram, Takuya Kato, Shuhei Okuyama, Makoto Kano, Peter L. Choyke, Hisataka Kobayashi  Published in: Cancer Letters Authors: Hiroshi Fukushima, Seiichiro Takao, Aki Furusawa, Vladimir Valera Romero, Sandeep Gurram, Takuya Kato, Shuhei Okuyama, Makoto Kano, Peter L. Choyke, Hisataka Kobayashi Enfortumab vedotin (EV), an antibody-drug conjugate (ADC) that targets Nectin-4, has shown promising results in the treatment of bladder cancer. The study investigated use of Nectin-4 targeting photoimmunotherapy in preclinical bladder cancer models. ML7710 was used as light source for activating the therapy in vitro and in vivo.   Read the article here

Rapid Depletion of Intratumoral Regulatory T cells Induces Synchronized CD8 T and NK Cell Activation and IFN-γ-dependent Tumor Vessel Regression

June 1, 2021 by Modulight
No comments
Published in: Cancer Research Authors: Yutaka Kurebayashi, Colleen P. Olkowski, Kelly C. Lane, Olga V. Vasalatiy, Biying C. Xu, Ryuhei Okada, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi, Noriko Sato    Published in: Cancer Research Authors: Yutaka Kurebayashi, Colleen P. Olkowski, Kelly C. Lane, Olga V. Vasalatiy, Biying C. Xu, Ryuhei Okada, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi, Noriko Sato   Tumor-infiltrating regulatory T cells (Tregs) were selectively depleted using anti-CD25 antibody fragment mediated NIR-PIT with ML7710 (50 J/cm2) in tumor-bearing mice. This induced transient IFN-γ expression in CD8 T and NK cells, which lead to efficient and rapid tumor vessel regression, intratumoral ischemia, and tumor necrosis/apoptosis and growth suppression. These results indicate the pivotal Continue reading →

Breaking the selectivity‑uptake trade‑off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi‑tier cancer targeting

January 2, 2020 by Modulight
No comments
Published in: Journal of Nanobiotechnology Authors: Barry J. Liang, Michael Pigula, Yan Baglo, Daniel Najafali , Tayyaba Hasan, Huang‑Chiao Huang    Published in: Journal of Nanobiotechnology Authors: Barry J. Liang, Michael Pigula, Yan Baglo, Daniel Najafali , Tayyaba Hasan, Huang‑Chiao Huang   The ML6600 laser was used to test the PDT efficacy of a novel photoimmunoconjugate-nanoliposome (PIC-Nal) comprising of EGFR-targeted Cetuximab, BPD photosensitizer and irinotecan chemoterapy inside a liposome. Different cancer cell lines were used and cell viability was determined after PDT.   Read the article here